Every AI newsletter, investors ask questions on the investor interaction platform: Hello, secretary. Does your company produce traditional Chinese medicine to fight the epidemic for the people of Jilin? How much of your company’s profit from the sale of traditional Chinese medicine?
Jilin Aodong Pharmaceutical Group Co.Ltd(000623) ( Jilin Aodong Pharmaceutical Group Co.Ltd(000623) .SZ) said on the investor interaction platform in April 2nd. In March 30, 2022, the company received the urgent notice on Further Strengthening the prevention and intervention of Chinese medicine in COVID-19 pneumonia in Jilin Province under the leadership of the New Coronavirus pneumonia epidemic prevention and control office in Yanbian province. One of the two companies is Jilin Aodong Pharmaceutical Group Co.Ltd(000623) , Limited by Share Ltd pharmaceutical company, which has sufficient raw materials and batch processing capacity. The subsidiary Jilin Aodong Pharmaceutical Group Co.Ltd(000623) Shihang Pharmaceutical Co., Ltd. can carry out order processing in the way of market-oriented supply guarantee. As of March 30, 2022, the company’s subsidiaries have provided about 1.21 million pairs of traditional Chinese medicine decoction, granules and other products. According to the preliminary calculation of the financial department, the operating income of these products is about 24.33 million yuan. For details, you can refer to the voluntary information disclosure announcement on the production of covid-19 Chinese medicine for the prevention and control of pneumonia disclosed by the company. As of the first half of 2021, the operating revenue of the company’s proprietary Chinese medicine accounted for 63.26% of the total operating revenue.
